Skip to main content
Premium Trial:

Request an Annual Quote

SNPs Souped-up Mass Spec Gives Edge to Peoples Genetics

Premium

Around Peoples Genetics, Barry Karger is known as the man behind the machine. That machine happens to be what the company believes will ensure its place in the industry: the ultra-sensitive High-Throughput Mutational Spectrometer, a tweaked mass spec co-developed with SpectruMedix that allows for SNP-discovery studies on a grand scale.

Peoples Genetics, founded two years ago in Woburn, Mass., relies on a patented form of capillary electrophoresis pioneered by Karger, who began working in the area for the Human Genome Project. “We spent the first year and a half really focusing on scaling the technology and on development of the instrumentation itself,” says COO KEVIN MOLLOY, 32.

Now, the company is ready to go public and is working to publish papers that will represent “the largest populations studied up to this date,” says Karger, 63. The company is working on pooled experiments including close to 100,000 people.

Unlike most SNP-discovery firms, Peoples Genetics skips the early round of identifying a SNP in a small group of samples. “We do massive-scale discovery and quantitation experiments,” Molloy says, so in theory, they’re more likely to find a disease-related SNP than companies relying on smaller studies.

“These common complex diseases are multigenic, but we overlay on top of that our expectation that each one of those genes would be multi-allelic,” Molloy says. “You’re not looking at one event in the genome, or even tens of events, but hundreds of events in the genome.”

“SNPs can be useful in a variety of ways,” Karger adds. “But to be able to make definitive calls … one needs to dive much deeper than SNPs.” He regards wildly different results in published SNP-study papers as evidence that people aren’t yet using big enough populations for the studies. “You need large populations to be able to make statistically meaningful calls.”

The 20-person company has a two-pronged business model, planning to sell access to sample libraries and platform technology to pay the early bills, with the long-term goal of sustainability from internal candidate gene experiments.

— Meredith Salisbury

 

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.